Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 97 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Multiparametric MRI Clear all

Conditions: Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Benign
Interventions: Clemastine Fumarate, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer Diagnosis
Interventions: PSMA PET scan, No PSMA PET, 18F- DCFPyl Injection; Diagnostic Test · Other · Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Bipolar Radiofrequency Focal Ablation; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioblastoma
Interventions: Positron Emission Tomography, Computed Tomography, Multiparametric Magnetic Resonance Imaging Scan, Fludeoxyglucose F-18, fluorine F 18 fluorodopa; Procedure · Radiation
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
Interventions: Apalutamide, Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Guided Stereotactic Body Radiation Therapy, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration; Drug · Procedure · Other + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
Interventions: Biopsy of Prostate, Decipher Prostate Cancer Test, Flotufolastat F-18 Gallium, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Radical Prostatectomy; Procedure · Genetic · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2035
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: Standard of Care Biopsy; Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 29 participants
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Prostate Cancer
Interventions: Targeted Biopsy; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Focal Laser Ablation; Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Focal-Fusion Bx; Device
Lead sponsor: Focal Healthcare Inc.; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Sarasota, Florida

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, High-Dose Rate Brachytherapy, Multiparametric Magnetic Resonance Imaging, PSMA PET Scan, Questionnaire Administration; Procedure · Radiation · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 40 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Carcinoma
Interventions: ultiparametric Magnetic Resonance Imaging, Perflutren lipid microsphere, Transrectal Ultrasound, Biopsy of Prostate; Procedure · Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Multi-Parametric MRI, MRI-Guided Biopsy; Device
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 85 Years · Male only
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation, BRCA1 Mutation, ATM Gene Mutation, MMR Mutation, Lynch Syndrome, Genetic Predisposition to Disease
Interventions: Prostate cancer screening; Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 35 Years to 74 Years · Male only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2040
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: MRI, PSA Blood Test; Device · Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer (Diagnosis)
Interventions: Not listed
Lead sponsor: Xiangya Hospital of Central South University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Adenocarcinoma, Prostate Cancer
Interventions: Transvesical Single Port Robotic Partial Prostatectomy, High-intensity focused ultrasound (HIFU); Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older · Male only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HER2-positive Breast Cancer
Interventions: MRI, Trastuzumab; Device · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Brain Neoplasm
Interventions: Biospecimen Collection, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Questionnaire Administration; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Multiparametric MRI, Prostate biopsy; Device · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Genetic Assessment; Genetic
Lead sponsor: Endeavor Health; Other
Eligibility: 40 Years to 69 Years · Male only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Bladder Cancer Stage II
Interventions: MRI imaging of the pelvis/bladder, genomic analysis of tumor; Diagnostic Test
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: pHLIP® ICG NIRF imaging; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Montvale, New Jersey • New York, New York

Conditions: Prostate Cancer
Interventions: Sonablate HIFU device; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 100 participants
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

PSMA PET Scan and mpMRI for Prostate Cancer Detection

MRI-Targeted Focal Ablation of the Prostate in Men With Prostate Cancer

FDG and FDOPA PET Demonstration of Functional Brain Abnormalities

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial

rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance

MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy

Use of Multi-Parametric MRI With Prostate Biopsy for Cancer Diagnosis.

Focal Laser Ablation of Prostate Cancer: A Feasibility Study Using MRI/US Image Fusion for Guidance

Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer

MRI Based Active Selection for Treatment Trial

Prostate Cancer Genetic Risk Evaluation and Screening Study

Early Changes In Multiparametric MRI In Prostate Cancer

Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT

Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation

A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer

Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy

Radiogenomics of Muscle Invasive Bladder Cancer

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery

HIFU for Focal Ablation of Prostate Tissue: An Observational Study